These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23425999)

  • 1. Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.
    Friedman GK; Spiller SE; Harrison DK; Fiveash JB; Reddy AT
    J Pediatr Hematol Oncol; 2013 Apr; 35(3):e123-6. PubMed ID: 23425999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
    Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
    Shields LB; Kadner R; Vitaz TW; Spalding AC
    Radiat Oncol; 2013 Apr; 8():101. PubMed ID: 23618500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
    Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
    J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years.
    Matsuda KI; Sakurada K; Nemoto K; Kayama T; Sonoda Y
    Int J Clin Oncol; 2018 Oct; 23(5):820-825. PubMed ID: 29796740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
    Kilickap S; Oztoprak I; Yucel B
    Acta Oncol; 2012 Apr; 51(4):544-6. PubMed ID: 22201408
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
    Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML
    J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and Management of Spinal Metastasis of Glioblastoma.
    Tai P; Dubey A; Salim M; Vu K; Koul R
    Can J Neurol Sci; 2015 Nov; 42(6):410-3. PubMed ID: 26310615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
    Vauleon E; Mesbah H; Gedouin D; Lecouillard I; Louvel G; Hamlat A; Riffaud L; Carsin B; Quillien V; Audrain O; Lesimple T
    Bull Cancer; 2012 Feb; 99(2):121-6. PubMed ID: 22257744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
    Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
    Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
    Clarke JL; Molinaro AM; Phillips JJ; Butowski NA; Chang SM; Perry A; Costello JF; DeSilva AA; Rabbitt JE; Prados MD
    Neuro Oncol; 2014 Jul; 16(7):984-90. PubMed ID: 24637230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
    Zaky W; Wellner M; Brown RJ; Blüml S; Finlay JL; Dhall G
    Pediatr Hematol Oncol; 2013 Oct; 30(7):623-32. PubMed ID: 24050762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Our experience with targeted therapy in glioblastoma multiforme].
    Kiss E; Lahm E; Vachaja J; Nagy P; Bazsó P; Fekete Z; Takácsi-Nagy Z; Pápai Z
    Magy Onkol; 2013 Dec; 57(4):264-8. PubMed ID: 24353992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
    Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
    Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
    Wong ET; Lok E; Swanson KD
    Cancer Med; 2015 Mar; 4(3):383-91. PubMed ID: 25620708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avastin: more questions than answers. .
    Desjardins A; Sampson JH
    J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
    Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
    J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
    Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
    J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
    Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
    Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.